Deals Shaping the Medical Industry (06/2010)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.
An advisory body to the UK government recommends a single-dose limit of 50 micrograms tetrahydrocannabinol (THC) for cannabidiol food products sold in the country. An analysis by Canna Consultants suggests this might translate in practice to today's widely assumed, although technically false, 0.2mg per retail unit limit.
Stada is investing nearly €50m in a Romanian supply-chain hub that it says will support future growth for the company, benefiting from its central European location. Meanwhile, the company has also struck medical cannabis deals with German insurers AOK and IKK.